Loading...
Please wait, while we are loading the content...
Similar Documents
Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| Content Provider | SAGE Publishing |
|---|---|
| Author | Kim, Chang Gon Hwang, Sang Hyun Kim, Kyung Hwan Yoon, Hong In Shim, Hyo Sup Lee, Ji Hyun Han, Yejeong Ahn, Beung-Chul Hong, Min Hee Kim, Hye Ryun Cho, Byoung Chul Cho, Arthur Lim, Sun Min |
| Copyright Year | 2022 |
| Abstract | Predictive markers for treatment response and survival outcome have not been identified in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemoimmunotherapy. We aimed to evaluate whether imaging biomarkers of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and routinely assessed clinico-laboratory values were associated with clinical outcomes in patients with advanced NSCLC receiving pembrolizumab plus platinum-doublet chemotherapy as a first-line treatment.Methods:We retrospectively enrolled 52 patients with advanced NSCLC who underwent baseline 18F-FDG PET/CT before treatment initiation. PET/CT parameters and clinico-laboratory variables, constituting the prognostic immunotherapy scoring system, were collected. Optimal cut-off values for PET/CT parameters were determined using the maximized log-rank test for progression-free survival (PFS). A multivariate prediction model was developed based on Cox models for PFS, and a scoring system was established based on hazard ratios of the predictive factors.Results:During the median follow-up period of 16.7 months (95% confidence interval: 15.7–17.7 months), 43 (82.7%) and 31 (59.6%) patients experienced disease progression and death, respectively. Objective response was observed in 23 (44.2%) patients. In the multivariate analysis, maximum standardized uptake value, metabolic tumour volume2.5, total lesion glycolysis2.5, and bone marrow-to-liver uptake ratio from the PET/CT variables and neutrophil-to-lymphocyte ratio (NLR) from the clinico-laboratory variables were independently associated with PFS. The scoring system based on these independent predictive variables significantly predicted the treatment response, PFS, and overall survival.Conclusion:PET/CT variables and NLR were useful biomarkers for predicting outcomes of patients with NSCLC receiving pembrolizumab and chemotherapy as a first-line treatment, suggesting their potential as effective markers for combined PD-1 blockade and chemotherapy. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/17588359211068732?download=true |
| ISSN | 17588359 |
| Volume Number | 14 |
| Journal | Therapeutic Advances in Medical Oncology (TAM) |
| e-ISSN | 17588359 |
| DOI | 10.1177/17588359211068732 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2022-01-09 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © The Author(s), 2022 |
| Subject Keyword | 18F-FDG PET/CT treatment outcome chemoimmunotherapy non-small-cell lung cancer predictive model |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
